- COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS
-
The present disclosure provides novel polypeptide-therapeutic compound or hormone-therapeutic compound conjugates using cleavable or non-cleavable linkers, whereby the polypeptide or hormone serves to target specific cells using receptor expression on the targeted cell to bind the ligand (polypeptide or hormone) carrying the therapeutic compound unlike antibody drug conjugates. Upon binding, the ligand and the therapeutic compound (multiples of the therapeutic compound in some embodiments) enter the cell by receptor-mediated endocytosis, and release drugs conjugated to the ligand by linkers, to interact with intracellular components to enhance, restore, or block a signal transduction process. The ligands for the polypeptide-therapeutic compound or hormone-therapeutic compound conjugates include, but are not limited to: cytokines, growth factors and hormones among other proteins with corresponding cell surface specific receptors. The disorders targeted by such polypeptide-therapeutic compound or hormone-therapeutic compound conjugates include, but are not limited to: immunological disorders (e.g., allergy and autoimmune disorders) and cancer.
- -
-
Paragraph 0577; 0579
(2020/02/06)
-
- Effect of maleimide-functionalized gold nanoparticles on hybrid biohydrogels properties
-
The role of well-dispersed gold nanoparticles as cross-linking agents in nanocomposite hydrogel formation was studied. Maleimide-coated gold nanoparticles were synthesized and used for Diels-Alder cycloaddition with furan modified gelatin. Hydrogel formation was aided by additional amide coupling of the modified gelatin with chondroitin sulfate. The cross-linking ability of the functionalized nanoparticles was evaluated and the final hydrogel properties were compared to those of a hybrid hydrogel containing inert-linker coated gold nanoparticles. The storage modulus of the nanoparticle cross-linked nanocomposites was 2.5-3 times compared to the controls. The presence of nanoparticles also affected the swelling properties, resulting in lower swelling ratios due to the formation of the more cross-linked structures. Conducted drug delivery experiments and the study of the light irradiation on the drug release behavior revealed promising features for the applications of nanocomposite polymer for drug delivery.
- García-Astrain,Ahmed,Kendziora,Guaresti,Eceiza,Fruk,Corcuera,Gabilondo
-
p. 50268 - 50277
(2015/06/25)
-
- NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF
-
The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures.
- -
-
-
- NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME
-
The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.
- -
-
-
- Novel Binder-Drug Conjugates (ADCs) and Use of Same
-
The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.
- -
-
-
- NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF
-
The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.
- -
-
-